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PPARγIn this study, HepG2-hepatitis B virus (HBV)-stable cells that did not overexpress HBx and HBx-deﬁcient
mutant-transfected cells were analyzed for their expression of HBV-induced, upregulated adipogenic and
lipogenic genes. The mRNAs of CCAAT enhancer binding protein α (C/EBPα), peroxisome proliferator-
activated receptor γ (PPARγ), adiponectin, liver X receptor α (LXRα), sterol regulatory element binding
protein 1c (SREBP1c), and fatty acid synthase (FAS) were expressed at higher levels in HepG2–HBV and
lamivudine-treated stable cells and HBx-deﬁcient mutant-transfected cells than in the HepG2 cells.
Lamivudine treatment reduced the mRNA levels of PPARγ and C/EBPα. Conversely, HBV replication was
upregulated by adiponectin and PPARγ agonist rosiglitazone treatments and was downregulated by
adiponectin siRNAs. Collectively, our results demonstrate that HBV replication and/or protein expression,
even in the absence of HBx, upregulated adipogenic or lipogenic genes, and that the control of adiponectin
might prove useful as a therapeutic modality for the treatment of chronic hepatitis B.l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Hepatitis B virus (HBV) infection is a serious public health
problem, with more than 350 million people worldwide suffering
from chronic hepatitis B (CHB). Between 15% and 40% of HBV-infected
patients will ultimately develop cirrhosis, liver failure, and hepato-
cellular carcinoma (HCC) (Lok, 2002). Chronic viral hepatitis C (CHC)
and CHB are both frequently associated with hepatic steatosis. The
frequency of steatosis in CHB ranges between 27% and 51%, whereas
the frequency of steatosis in CHC ranges between 31% and 72%
(Gordon et al., 2005). The molecular mechanism underlying hepatitis
C virus-mediated hepatic steatosis, which can lead to ﬁbrosis and
cancer, has been the subject of extensive study (Powell et al., 2005;
Sheikh et al., 2008); however, the mechanism underlying HBV-
mediated hepatic steatosis remains incompletely understood.
It was shown recently that overexpression of the hepatitis B virus
X (HBx) protein induces peroxisome proliferator-activated receptor γ
(PPARγ) gene expression and transcriptional activation, leading to the
upregulation of the fatty acid uptake-associated gene CD36 and of
several adipogenic genes, including adipsin, aP2, and adiponectin
(Kim et al., 2007a; Na et al., 2009). In addition to PPARγ, the
overexpression of HBx also upregulates the sterol regulatory element-
binding protein 1 (SREBP1) gene (Kim et al., 2007a; Na et al., 2009).
The enhanced transcriptional activation of SREBP1 may lead tohepatic steatosis via an induced expression of lipogenic genes,
including fatty acid synthase (FAS) (Kim et al., 2007a; Na et al.,
2009). Furthermore, upregulated SREBP1, FAS, and PPARγ in HBx-
overexpressed cells and transgenic mice was attributed to the
upregulated expression of the liver X receptor (LXR), thus indicating
that HBx-induced lipogenesis occurred in an LXR-dependent manner
(Kim et al., 2008; Na et al., 2009). A cDNA microarray analysis of
transgenic mouse livers harboring the HBV replicate revealed that
HBV upregulates genes associated with lipid biosynthesis (Hajjou
et al., 2005). A more recent study using proteomics and metabolomics
techniques demonstrated that HBV protein expression in transgenic
mouse livers alters lipid metabolism in vivo (Yang et al., 2008).
The LXRs, LXRα and LXRβ, are ligand-activated transcription factors
belonging to the nuclear receptor superfamily that perform critical roles
in the regulation of hepatic lipogenesis via SREBP1c, leading to hepatic
steatosis (Baranowski, 2008). TwoSREBP1s, SREBP1a and SREBP1c, both
of which are members of the basic helix–loop–helix–leucine zipper
family of transcription factors, regulate fatty acid synthesis in the liver,
inducing hepatic steatosis by upregulating the expressions of genes
involved in hepatic fatty acid synthesis, including FAS, acetyl-CoA
carboxylase (ACC), and stearoyl CoA desaturase (SCD) (Eberlé et al.,
2004).
PPAR types α, β/δ, and γ are transcription factors belonging to the
nuclear receptor superfamily (Tontonoz et al., 1994a). PPARγ is an
adipocyte-speciﬁc nuclear hormone receptor, and a key regulator of the
adipocyte differentiation and gene expression associatedwith fatty acid
and glucose metabolism (Tontonoz et al., 1994b; Tontonoz and
Spiegelman, 2008). PPARγupregulates several adipogenic and lipogenic
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adipocyte fatty acid-binding protein 4, FAS, and ACC in the liver, thereby
suggesting a putative role for PPARγ in the development of hepatic
steatosis in a murine model (Gavrilova et al., 2003; Schadinger et al.,
2005; Yu et al., 2003). Therefore, PPARγ appears to regulate lipid
synthesis, transport, and storage in hepatocytes, thus leading to the
development of hepatic steatosis.
Adiponectin, a novel adipose tissue-speciﬁc protein with putative
anti-atherogenic and anti-inﬂammatory effects (Funahashi et al.,
1999; Yokota et al., 2000), is expressed at abnormally low levels in
patients with obesity, type 2 diabetes mellitus, and coronary heart
disease (Arita et al., 1999; Hotta et al., 2000; Ouchi et al., 1999). Levels
of adiponectin are also elevated in liver cirrhosis (Tietge et al., 2004).
In a clinical study of human subjects with chronic hepatitis, HBV-
infected patients evidenced signiﬁcantly higher adiponectin levels
than HCV-infected patients and normal controls, and adiponectin
levels in HBV-infected patients were reduced in response to IFN-α
treatment (Lu et al., 2005). Although adiponectin is believed to be
associated with HBV infection, little is currently known regarding the
relationship between adiponectin levels and HBV replication.
Although HBV purportedly induces steatosis, it remains to be
determined whether or not HBV-induced, upregulated adipogenic
genes can affect HBV replication. In this study, we determined that
HBV replication without HBx overexpression or even in the absence of
HBx, increased the expression of the CCAAT enhancer binding proteinα
(C/EBPα), PPARγ and adiponectin, a downstream target gene of PPARγ.
LXRα, SREBP1c, and FASwere also increased inHepG2–HBV-stable cells
and HBx-deﬁcient mutant-transfected cells. When we inhibited HBV
replication using lamivudine, a nucleoside reverse transcriptase (RT)
inhibitor, C/EBPα, PPARγ, adiponectin, LXRα, SREBP1c, and FASmRNAs
were still expressed at higher levels than in the HepG2 cells. We
demonstrated that this HBV replication-induced increase in adiponectin
levels could further enhance HBV DNA replication, by applying
adiponectin or the PPAR agonist rosiglitazone to theHepG2–HBV-stable
cells or to the isolated core particles, which also caused a further in-
crease in HBV DNA synthesis. We also demonstrated that the reduction
in adiponectin levels induced by adiponectin siRNA treatment might
inhibit HBV DNA replication. We suggest that adiponectin may
strengthen interactions between the HBV P protein and pgRNA and/or
synthesized HBV DNA, which could consequently enhance endogenous
HBV DNA polymerase activity in core particles. Collectively, our results
indicate that HBV may promote the expression of lipogenic and
adipogenic genes that might induce hepatic steatosis and that these
HBV-induced adipogenic genes, such as adiponectin, upregulate HBV
replication.
Results
HBV replication induces lipogenic and adipogenic gene expressions in
HepG2–HBV-stable cells
LXRs, SREBP1s, and PPARγ are believed to perform critical roles in
hepatic steatosis (Yu et al., 2003; Baranowski, 2008; Tontonoz and
Spiegelman, 2008). It was demonstrated previously that HBx over-
expression results in increased expressions of lipogenic and adipogenic
genes, including LXRs, SREBP1c, and PPARγ and also leads to hepatic
lipid accumulation in HBx-stable and -transfected cells, and -transgenic
mice (Kimet al., 2007a, 2008;Na et al., 2009). Additionally, C/EBPα gene
expression was enhanced by HBx, and the enhanced C/EBPα could
subsequently upregulate and activate PPARγ (Kim et al., 2007a). Via
enhanced PPARγ expression, adiponectin, a downstream target gene of
PPARγ, was upregulated in HBx-overexpressed cells and -transgenic
mice (Kim et al., 2007a). Therefore, in this study, we attempted to
determine whether HBV DNA replication in HepG2–HBV-stable cells
(Fig. 1A), inwhichHBxwasnot overexpressed, affects the expressions of
lipogenic and adipogenic genes (Fig. 1B). ThemRNA expression levels ofC/EBPα, PPARγ, adiponectin, LXRα, SREBP1c, and FASwere assessed by
RT-PCR in HepG2 control cells andHepG2–HBV-stable cells (Hong et al.,
2007), a cell line that is stably transfected with pPB, the partially
redundant wild-type HBV of subtype adw R9 (Kim et al., 2004). The
mRNA expression levels of these genes were increased in HepG2–HBV-
stable cells, but not in HepG2 cells (Fig. 1B). When we inhibited HBV
DNA synthesis using lamivudine (Fig. 1A), the mRNA expression levels
of C/EBPα, PPARγ, adiponectin, LXRα, SREBP1c, and FAS were still
expressed more abundantly than in HepG2 cells (Fig. 1B). PPARγ and
adiponectin proteins were expressed at higher levels in HepG2–HBV
and lamivudine-treated stable cells than in HepG2 cells (Fig. 1B).
Consistent with the RT-PCR results, the mRNAs of C/EBPα, PPARγ,
adiponectin, SREBP1c, and FAS were expressed at higher levels in
HepG2–HBV and lamivudine-treated stable cells than in HepG2 cells,
according to the results of quantitative real-time RT-PCR (Fig. 1C). The
mRNAs of adiponectin, SREBP1c, and FAS from the lamivudine-treated
stable cells were compatible with the HepG2–HBV-stable cells,
evidencingnosigniﬁcant reduction as the result of lamivudine treatment
(Fig. 1C). These results demonstrate that HBV replication and/or
expressions ofHBVproteinswithoutHBxoverexpression canupregulate
the expression of C/EBPα, PPARγ, adiponectin, LXRα, SREBP1c, and FAS.
HBV replication in transiently transfected cells, even in the absence of
HBx, induces lipogenic and adipogenic gene expressions
After analyzing lipogenic and adipogenic gene expressions in HBV-
replicating stable cells (Fig. 1), we assessed the expressions of these
genes in the HBV wt-transfected HepG2 cells. The mRNA expression
levels of C/EBPα, PPARγ, adiponectin, LXRα, SREBP1c, and FAS were
increased in the HBVwt-transfected HepG2 cells relative to the HepG2
cells (Fig. 2C). We also evaluated lipogenic and adipogenic gene
expression levels in HBx-deﬁcient mutant-transfected HepG2 cells, in
which HBx expression was abolished completely by site-directed
mutagenesis (Fig. 2A). Since it had been previously reported that the
HBx-deﬁcient HBV mutant in HepG2 cells replicates at much lower
levels than the HBV wt virus (Melegari et al., 2005; Bouchard et al.,
2001), the HBV replication of HBx-deﬁcient HBV mutant was
monitored by Southern blotting (Fig. 2B). Consistentwith the previous
reports (Melegari et al., 2005; Bouchard et al., 2001), Southern blotting
revealed the reduced levels of synthesis of partially double-stranded
relaxed circular (RC), double-stranded linear (DL), and single-
stranded (SS) DNA synthesis from HBx-deﬁcient mutant-transfected
HepG2 cells (Fig. 2B). The mRNA expression levels of C/EBPα, PPARγ,
adiponectin, LXRα, SREBP1c, and FAS in the HBx-deﬁcient mutant-
transfected HepG2 cells were higher than in the HepG2 cells and were
compatible with those of HBV wt-transfected HepG2 cells (Fig. 2C).
PPARγ and adiponectin proteins were also increased in the HBV wt-
and HBx-deﬁcient mutant-transfected HepG2 cells (Fig. 2C).
Using quantitative real-time RT-PCR, the mRNAs of C/EBPα,
PPARγ, adiponectin, SREBP1c, and FAS were analyzed—the results
demonstrated that, consistent with the results of RT-PCR, these genes
were expressed more abundantly in HBV wt- and HBx-deﬁcient
mutant-transfected HepG2 cells than in HepG2 cells (Fig. 2D). The
expression of lipogenic and adipogenic gene expressions in HBx-
deﬁcient mutant-transfected HepG2 cells were compatible with those
observed in the HBV wt-transfected cells. C/EBPα was expressed at
higher levels in the HBx-deﬁcient mutant-transfected HepG2 cells
than in the wt-transfected cells.
Activated PPARγ and increased adiponectin enhance HBV DNA
replication without changes in pgRNA encapsidation and core
particle formation
In order to determine whether PPARγ activation or inhibition, FAS
inhibition, or increased adiponectin can inﬂuence HBV DNA synthesis,
HepG2–HBV-stable cells were treated for 48 h with rosiglitazone (a
Fig. 1. Effects of HBV replication on lipogenic and adipogenic gene expressions in HepG2–HBV-stable cells. (A) Southern blot analysis to demonstrate the inhibited HBV replication by
lamivudine from HepG2–HBV-stable cells. HBV DNA was extracted from isolated core particles, separated, transferred to nylon membranes, hybridized with a random-primed 32P-
labeled HBV-speciﬁc probe, and subjected to autoradiography. The single- and double-stranded linear and partially double-stranded relaxed circular forms of HBV DNA are marked
with SS, DL, and RC, respectively. (B) RT-PCR andWestern blot to characterize adipogenic and lipogenic mRNAs and PPARγ and adiponectin proteins. Total RNAs were prepared from
HepG2, HepG2–HBV-stable, and lamivudine-treated HepG2–HBV-stable cells and RT-PCR was conducted as described in the Materials and methods section. The equivalence of
mRNA loading in the lanes was conﬁrmed via GAPDH expression. For Western blot analysis, equivalent amounts of total cell lysates were analyzed using anti-PPARγ and anti-
adiponectin antibodies. (C) Quantitative real-time RT-PCT. Total RNA was prepared as described in Fig. 1B. *Pb0.05 vs. control, **Pb0.01 vs. control, and ***Pb0.001 vs. control
(n=5).
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inhibitor), or adiponectin (Fig. 3). C protein expression, core particle
formation, and pgRNA encapsidation were not inﬂuenced by drug
treatments (Fig. 3A and B), thus demonstrating that themodulation of
PPARγ, FAS, or adiponectin has no effect on C protein expression,
intracellular core particle formation, and pgRNA encapsidation in
HepG2–HBV-stable cells. It should be noted here that since pgRNA
transcription was controlled by the CMV IE promoter (Kim et al.,
2004; Hong et al., 2007), pgRNA expression should be unaffected by
drug treatments.
We then attempted to determine, via Southern blot analysis,
whether HBV DNA synthesis is controlled by the modulation of
PPARγ, FAS, or adiponectin in drug-treated HepG2–HBV-stable cells.
HBV DNA synthesis was increased by 2.8- or 3.1-fold with rosiglita-
zone or adiponectin, respectively, but treatment of the cells with
T0070907 or cerulenin did not affect HBV DNA synthesis (Fig. 3C).
This result demonstrates that HBV DNA synthesis was enhanced by
PPARγ activation and by adiponectin, a downstream target gene of
PPARγ, in HepG2–HBV-stable cells, thus suggesting that the upregu-
lation of adiponectin induced by activated PPARγ could enhance the
synthesis of HBV DNA.
To exclude the possibility that rosiglitazone or adiponectin treat-
ment only increases HBV DNA synthesis in HepG2-derived cells, weconducted the same experiment with HuH7–HBV-stable cells (Kim
et al., 2007b) and detected similar enhancement of HBV replication
after rosiglitazone or adiponectin treatment (Fig. 3D).
While we were preparing this article demonstrating the increased
HBV replication as the result of rosiglitazone, a recent report claimed
that rosiglitazone can exert an inhibitory effect on HBV replication
(Wakui et al., 2010). We hypothesized that the difference between
our present study and this report might reside in the mode of pgRNA
transcription, which uses the CMV IE promoter and authentic core
promoter, respectively. To test this the effect of promoter, HepG2.2.15
cells, which have two dimers of HBV genome and use authentic
promoter for pgRNA transcription (Sells et al., 1987), were treated
with rosiglitazone and HBV replication was tested by Southern
blotting (Fig. 3E). To our surprise, HBV replication was increased by
rosiglitazone treatment in HepG2.2.15 cells, further supporting our
result (Fig. 3E).
Decreased HBV DNA replication by adiponectin downregulation
Considering that PPARγ and adiponectin expression levels were
increased in HBV replicating HepG2–HBV-stable cells (Fig. 1B and C)
and were further increased in a time-dependent manner by 6 days of
rosiglitazone treatment (Supplementary Fig. 1), we reasoned that
Fig. 2. Lipogenic and adipogenic gene expressions in HBV wt- and HBx-deﬁcient mutant-transfected HepG2 cells. (A) Schematic diagram of HBV wt and HBx-deﬁcient mutant
construct used for transient transfection. HBV sequences were depicted as thick lines, and  sequences at the 5′- and 3′-ends are marked. The ORFs are presented as open boxes, and
the cytomegalovirus (CMV) immediate early promoter is indicated with an open arrow. The positions of point mutation to completely abolish X protein are indicated by closed
arrowheads. (B) Southern blot analysis to detect HBV DNA replication in HBV wt- and HBx-deﬁcient mutant-transfected HepG2 cells. Southern blot analysis was conducted as
described for Fig. 1A. The single- and double-stranded linear, and partially double-stranded relaxed circular forms of HBV DNA are labeled as SS, DL, and RC, respectively. (C) RT-PCR
to determine the mRNA expressions of adipogenic and lipogenic genes andWestern blotting for PPARγ and adiponectin proteins. Total RNAs were prepared for RT-PCR from HepG2,
HBVwt-, and HBx-deﬁcient mutant-transfected HepG2 cells. RT-PCR was conducted as described in theMaterials andmethods section. The equivalence of mRNA loading in the lanes
was conﬁrmed by GAPDH expression. ForWestern blot analysis, equivalent amounts of total cell lysates were analyzedwith anti-PPARγ and adiponectin antibodies. (D) Quantitative
real-time RT-PCR. Total RNA was prepared as described in Fig. 1B. *Pb0.05 vs. control, **Pb0.01 vs. control, and ***Pb0.001 vs. control (n=5).
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activation of PPARγ, could increase HBV DNA synthesis. We also
detected increased HBV replication as the result of direct adiponectin
treatment (Figs. 3 and 5). From these results, we hypothesized that
adiponectin can control HBV DNA synthesis, such that downregulated
adiponectin may also inhibit HBV DNA synthesis. To evaluate the
hypothesis that adiponectin controls HBV DNA synthesis without
affecting pgRNA encapsidation, HepG2–HBV-stable cells were trans-
fected with adiponectin siRNAs to characterize the effects of
adiponectin silencing (Fig 4A). This silencing was found to result in
an 80% reduction of HBVDNA synthesis (Fig. 4C), with no concomitant
change in the encapsidation of pgRNA (Fig. 4B). Collectively, our data
demonstrate that PPARγ activation followed by the upregulation
of adiponectin—a downstream target gene of PPARγ—increases
HBV DNA synthesis, and that the downregulation of adiponectin by
adiponectin siRNA inhibits the synthesis of HBV DNA.
To further conﬁrm that adiponectin expression was induced via
the rosiglitazone-mediated activation of PPARγ, the adiponectinsiRNA experiment was performed in the presence of rosiglitazone in
HepG2–HBV-stable cells (Supplementary Fig. 2). Consistent with
Fig. 4A, adiponectin siRNA decreased adiponectin protein level (0.51).
Even though it was only a marginal increase (1.18), rosiglitazone
treatment increased adiponectin protein level. By rosiglitazone plus
adiponectin siRNA, adiponectin protein level was marginally de-
creased (0.90), suggesting that rosiglitazone effect seems to be
blocked by adiponectin siRNA.
PPARγ and adiponectin enhance endogenous HBV DNA polymerase
activity independent of the transcriptional activation of host cell factors
PPARγ has been shown to affect the transcriptional activation of
several genes associated with fatty acid and glucose metabolism in
HepG2-HBx-stable cells (Kim et al., 2007a). In order to determine
whether this increasedHBV polymerase activity occurs independently
of the transcriptional activation of host genes or other host cell
factors, an endogenous polymerase assay (EPA) was conducted in the
Fig. 3. Effect of PPARγ modulators, FAS inhibitor, or adiponectin on core particle formation, pgRNA encapsidation, and HBV DNA replication. (A) Western blot analysis to detect C
protein and core particles from drug-treated HepG2–HBV-stable cells. HepG2–HBV-stable cells were treated with mock (M), rosiglitazone (R, 10 μM), T0070907 (T, 10 μM),
cerulenin (C, 10 μg/ml), or adiponectin (A, 0.1 μg/ml) for 48 h. ForWestern blot analysis of core particles (upper panel), isolated core particles were separated on a native agarose gel
and analyzed via immunoblotting with a rabbit anti-HBc antibody. For Western blot analysis (lower panel), the cell lysates were subsequently separated via SDS-PAGE, and the C
protein was detected by immunoblot analysis with an anti-HBc antibody. The expression of tubulin was used as an internal control for sample loading. (B) RNase protection assay
(RPA) to detect HBV cytoplasmic and encapsidated pgRNA from drug-treated HepG2–HBV-stable cells. An in vitro transcribed radiolabeled antisense RNA probe (446 nt) was
hybridized overnight at 50 °C with pgRNA from isolated core particles or 10 μg total RNA. Protected pgRNA (369 nt) following RNase digestion was run on a 5% polyacrylamide–8 M
urea gel and visualized by autoradiography. The left panel shows encapsidated pgRNA from isolated core particles, and the right panel depicts cytoplasmic pgRNA. (C) Southern blot
analysis to detect HBV DNA replication from drug-treated HepG2–HBV-stable cells. HepG2–HBV-stable cells were treated with drugs for 48 h, and HBV DNA was extracted from
isolated core particles, separated, transferred to nylon membranes, hybridized with a random-primed 32P-labeled HBV-speciﬁc probe, and subjected to autoradiography.
(D) Southern blot analysis to detect HBV DNA replication from drug-treated HuH7–HBV-stable cells. HuH7–HBV-stable cells were treated withmock (M), rosiglitazone (R, 10 μM), or
adiponectin (A, 0.1 μg/ml) for 48 h. Southern blot analysis was conducted as described for Fig. 1A. The relative levels of HBV DNA from isolated core particles were measured with the
Fujiﬁlm Image Gauge V4.0 program. (E) Southern blot analysis to detect HBV DNA replication from rosiglitazone-treated HepG2.2.15 cells. HepG2.2.15 cells were treated with mock
(M) or rosiglitazone (R, 10 μM) for 48 h. Southern blot analysis was conducted as described for Fig. 1A. The single- and double-stranded linear and partially double-stranded relaxed
circular forms of HBV DNA are labeled as SS, DL, and RC, respectively.
294 S. Yoon et al. / Virology 409 (2011) 290–298presence of 32P-dATP for 1 day at 37 °C. In brief, cytoplasmic core
particles were isolated from HepG2–HBV- (Hong et al., 2007) and
HuH7–HBV (Kim et al., 2007b)-stable cells. During EPA, these isolated
core particles were incubated with rosiglitazone, T0070907, or
adiponectin. 32P-labeled HBV DNA were subsequently extracted and
electrophoresed on 1% agarose gels and subjected to autoradiography.
32P-labeled DNAs from rosiglitazone- or adiponectin-treated core
particles were increased up to 1.33- or 1.46-fold (Fig. 5A), or 1.45- or
1.69-fold (Fig. 5B), respectively. These results demonstrate that the
PPARγ- or adiponectin-mediated increases in HBV endogenous
polymerase activity in the core particles occur independently of the
transcriptional upregulation of host cell factors, thereby indicating
that enhanced endogenous DNA polymerase activity resulting from
rosiglitazone or adiponectin treatment can occur even in the complete
absence of transcriptional activation of the target genes. This further
suggests that adiponectin may act directly on core particles, in-
creasing endogenous polymerase activity by strengthening theinteractions between P protein–pgRNA and/or P protein–DNA com-
plexes, and/or between C proteins of the core particles.
Discussion
Many studies concerning the regulation of hepatic steatosis have
focused principally on mechanisms involving PPARγ (Gavrilova et al.,
2003; Kim et al., 2007a; Yu et al., 2003; Zhou et al., 2008). According to
these studies, deregulated PPARγ contributes to hepatic steatosis by
increasing hepatic triglyceride production and hepatic lipid uptake.
Additionally, the roles of LXRs and SREBP1s on hepatic steatosis have
been previously demonstrated in the regulation of hepatic lipo-
genesis by the increased gene expressions involved in hepatic fatty
acid synthesis, including FAS, ACC, and SCD (Eberlé et al., 2004;
Baranowski, 2008).
The molecular mechanisms underlying hepatic steatosis resulting
from the deregulation of hepatic lipogenesis by HBV have focused
Fig. 4. Inhibition of HBV DNA replication by adiponectin siRNAs. HepG2–HBV-stable cells were transfected with 20 nM of luciferase (Luc) or adiponectin siRNAs as described in the
Materials and methods section. (A) To detect adiponectin expression, the cell lysates were prepared 48 h after transfection, and immunoblot analyses were conducted using
antibodies against adiponectin and tubulin. (B) Cytoplasmic pgRNA expression and pgRNA encapsidation by adiponectin siRNA. RPA were conducted using siRNA-transfected
HepG2–HBV-stable cells as described for Fig. 3B. (C) The inhibition of HBV DNA replication by transfection with adiponectin siRNA in HepG2–HBV-stable cells. Southern blot analysis
was conducted as described in Fig. 1A. The single- and double-stranded linear, and partially double-stranded relaxed circular forms of HBV DNA are marked as SS, DL, and RC,
respectively. Similar results were obtained from two independent experiments. The relative levels of pgRNA and HBV DNA were measured with the Fujiﬁlm Image Gauge V4.0
program.
Fig. 5. Enhancement of endogenous polymerase activity by rosiglitazone or adiponectin. Isolated core particles from HepG2–HBV-stable cells (A) and HuH7–HBV-stable cells
(B) were incubated with EPA reaction buffer supplemented with mock (M), rosiglitazone (R, 10 μM), T0070907 (T, 10 μM), or adiponectin (A, 0.1 μg/ml) and 10 μCi of α-32P-dATP
(3000 Ci/mmol) and unlabeled dNTP mix at 37 °C overnight. Following EPA, 32P-labeled DNA was extracted, separated via 1% agarose gel electrophoresis, and subjected to
autoradiography. The single- and double-stranded linear, and partially double-stranded relaxed circular forms of HBV DNA are labeled as SS, DL, and RC, respectively. The relative
labeling intensities were measured with the Fujiﬁlm Image Gauge V4.0 program.
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2007a, 2008; Na et al., 2009). In this study, we demonstrate that HBV
replication and/or the expression of HBV proteins without HBx
overexpression, or even in the complete absence of HBx expression,
could induce adipogenic and lipogenic gene expressions, thus
showing that not only the HBx but also other HBV proteins and HBV
DNA replication could induce hepatic steatosis. We further demon-
strated that the upregulation of adiponectin pursuant to PPARγ gene
upregulation by HBV replication and/or other HBV protein expres-
sions, and/or the activation of PPARγ by rosiglitazone, further en-
hance the replication of HBV.
Adiponectin, a physiologically active polypeptide secreted by
adipose tissue, has become a focus of research interest in recent years.
Adiponectin has been shown to exert anti-diabetic, anti-obesity, anti-
atherogenic, and anti-inﬂammatory effects, identifying it as a promising
candidate for the treatment of obesity-mediated metabolic syndrome
(Matsuzawa et al., 2004; Tschritter et al., 2003). Adiponectin also exerts
direct effects on hepatocytes via the adipoR2 receptor (Yamauchi et al.,
2003), and its anti-inﬂammatory properties are mediated by its
antagonism of tumor necrosis factor-α (Ouchi et al., 2000), thereby
suggesting that adiponectinmay potentially playhepatoprotective roles
against liver ﬁbrosis and cirrhosis (Powell et al., 2005). It has been
previously reported that serum adiponectin levels in CHB were
increased in patients with advanced liver ﬁbrosis and decreased when
ﬁbrosis was reduced (Hui et al., 2007). After antiviral therapy, patients
with ﬁbrosis reduction evidenced a marked decline in serum adipo-
nectin levels (Hui et al., 2007). However, it was noted in a more recent
report that serum adiponectin is positively correlated with HBV DNA,
and the levels of serum adiponectin were reduced in Chinese CHB
patients with insulin resistance and hepatic steatosis (Wong et al.,
2010). These higher levels of serum adiponectin may contribute to the
observed reduction in hepatic steatosis (Wong et al., 2010). Researchers
into the subject also have claimed that CHB patients may have a lower
risk of metabolic syndrome, owing principally to increased adiponectin
production (Wong et al., 2010). The association between adiponectin
and liver injury in CHB remains somewhat controversial (Hui et al.,
2007; Wong et al., 2010), and this issue appears to be quite relevant to
the treatmentof CHBpatientswithmetabolic syndrome,which includes
type 2 diabetes, hypertension, obesity, and dyslipidemia; thus, this issue
will need to be solved in the future.
In parallel with the in vivo results reported in CHB patients (Wong
et al., 2010), our in vitroﬁndings also demonstrate thatHBV replication
was more profoundly enhanced by direct adiponectin treatment and
PPARγ activation using an agonist and declined as the result of
adiponectin siRNA treatment, demonstrating a positive correlation
between adiponectin and HBV replication. We also demonstrate that
HBV replication in HBV-stable and HBV-transfected cells can upregu-
late adiponectin via an induced increase in PPARγ gene expression
(Figs. 1 and 2): additionally, the inhibition of HBV replication by
lamivudine induces a reduction in PPARγ gene expression (Fig. 1C),
thus possibly leading to declining adiponectin expression. As HBV
replication was more markedly enhanced by PPARγ activation when
an agonist was employed, the transcriptional activities of PPARγ,
LXRα, and SREBP1c by HBV replication and/or HBV proteins, with the
exception of HBx, will require further testing in the future.
Acting independently of the transcriptional activation of host
factors, adiponectin was also shown to act directly on core particles to
increase HBV DNA synthesis by enhancing endogenous polymerase
activity. These results indicate that the adiponectin-mediated increase
of HBV polymerase activity might arise from the strengthened
interaction between the HBV P protein and pgRNA and/or synthesized
HBV DNA.We do not currently know precisely how or why the PPARγ
agonist, rosiglitazone, increases HBV DNA synthesis in isolated core
particles without transcriptional activation of the host factors (Fig. 5).
PPARγ may be present in the isolated core particle preparations, and
its activation by rosiglitazone may act directly on the core particles inthe absence of the transcriptional activation of the host genes. It is also
possible that rosiglitazone itself may act directly on the core particles,
in a fashion similar to that of adiponectin. These hypotheses will
require more testing in the future.
Unlike our present results revealing increased HBV replication as
the result of rosiglitazone, it was recently reported that rosiglitazone
can exert an inhibitory effect on HBV replication (Wakui et al., 2010).
At ﬁrst, we hypothesized that the difference between our present
study and this report might reside in the mode of pgRNA tran-
scription, which uses the CMV IE promoter and authentic core
promoter, respectively. However, HBV replication was increased by
rosiglitazone treatment in HepG2.2.15 cells (Fig. 3E), further
supporting our result. Nonetheless, the level of pgRNA transcription
induced by rosiglitazone and/or adiponectin treatment should, in the
future, be tested under the control of the authentic core promoter. As
our HBV construct employed the CMV IE promoter in order to ensure a
constant pgRNA level, we were able to focus on the effects of
rosiglitazone or adiponectin treatment on HBV DNA synthesis; our
results indicated increased HBV DNA synthesis, possibly occurring as
the result of enhanced polymerase activity.
Hepadnaviral reverse transcription occurs within the core parti-
cles, followed by the selective encapsidation of pgRNA. Both pgRNA
encapsidation and the initiation of DNA synthesis are triggered by the
binding of the terminal protein (TP) domain of the hepadnavirus P
protein to an encapsidation (epsilon, ) signal, the 5′-proximal RNA
stem–loop structure in pgRNA. Once the P protein is bound to , a
hydroxyl group of a Tyr residue in the TP domain functions as a primer
for the protein-primed synthesis of 3 or 4 nt from the bulge of ,
which are covalently linked to TP (priming reaction). Then P-linked
oligodeoxynucleotides are transferred to direct repeat 1 (DR1), at
which minus-strand elongation ensues. The minus-strand DNA is
further reverse-transcribed by the co-packaged P protein into DL- and
RC-DNA. During these processes, several chaperones, including Hsp70
and Hsp90, are indispensable for P protein activation (Hu and Boyer,
2006; Hu et al., 2004). Adiponectin might be a host factor that helps to
activate the P protein for reverse transcription, thus facilitating the
synthesis of HBV DNA.
Whenwedecreased the adiponectin level using adiponectin siRNA,
HBV replicationwas inhibited (Fig. 4), thus suggesting that the control
of adiponectin might be evaluated as a possible therapeutic modality
for the treatment of CHB, even though the levels of adiponectin and
HBV DNA should be monitored carefully in CHB patients, considering
their higher risks of liver ﬁbrosis, metabolic syndrome, and hepatic
steatosis.Materials and methods
Cell culture and isolation of core particles
HepG2 and HepG2.2.15 cells were maintained in Dulbecco's
modiﬁed Eagle'smedium supplementedwith penicillin, streptomycin,
and 10% fetal bovine serum.HepG2–HBV-stable cells (PEB8 cells)were
established by transfecting HepG2 cells with pPB, which encodes for a
partially redundant wild-type HBV of subtype adwR9 (Kim et al.,
2004), andweremaintained in 0.5 mg/ml G418 (Hong et al., 2007). To
generate the X-deﬁcient mutant of HBV, in which HBx expression was
completely abolished in the HBV wt background, three ATG start
codons in an HBx open reading frame were changed to TTGs via site-
directed mutagenesis. The transcription of pgRNA is controlled by a
cytomegalovirus immediate early (CMV IE) promoter (Kim et al.,
2004). To inhibit HBV DNA synthesis, HepG2–HBV-stable cells were
treated for 48 h with 4 μg/ml of lamivudine. HuH7–HBV-stable cells
(PUB9 cells) were prepared as previously described (Kim et al.,
2007b). Cytoplasmic core particles were prepared as previously de-
scribed (Kim et al., 2004).
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Total RNAs were isolated from HepG2, HepG2–HBV, and lamivu-
dine-treated HepG2–HBV cells using RNA stat 60 (Tel-test, Inc.).
Additionally, total RNAs fromHBVwt or X-deﬁcientmutant-transfected
HepG2 cells were isolated. cDNAs were synthesized from 5 μg of total
RNAs using oligo-dT and Superscript reverse transcriptase II, according
to the manufacturer's recommendations. The resultant cDNAs were
employed as templates for PCR ampliﬁcation. The sequences of the
primers used in these reactions are provided in Supplementary Table 1.
Quantitative real-time RT-PCR was also conducted in order to quantify
the expression levels of C/EBPα, PPARγ, adiponectin, SREBP1c, and FAS
mRNA. Primers for real-time RT-PCR are listed in Supplementary
Table 2.
siRNA transfection
The siRNA oligonucleotides for adiponectin were purchased from
Dharmacon. A luciferase siRNA (Dharmacon) was used as a control.
Transfection was conducted using Lipofectamin RNAiMAX (Invitro-
gen), in accordance with the manufacturer's instructions. In brief,
20 nM of siRNAwasmixedwith Lipofectamin RNAiMAX in serum-free
media. While the complexes were forming, the cells were diluted in
complete growth medium without antibiotics, resulting in an ~30–
50% conﬂuence at 24 h after plating, after which they were mixed
with the siRNA-Lipofectamin RNAiMAX complexes. Forty-eight hours
after transfection, the lysates were prepared.
Southern blot analysis and RNase protection analysis (RPA)
To analyze HBV DNA synthesis, core DNA was extracted and
Southern blotting was conducted as previously described (Kim et al.,
2004). In order to analyze the cytoplasmic and encapsidated pgRNA,
RPA was conducted as described previously (Kim et al., 2004). A
portion (446 nt) of the HBV sequence (nt 1805 to 2187) was syn-
thesized in vitro, and the protected sequence was measured to be
369 nt long (Kim et al., 2004).
Endogenous polymerase assay (EPA)
Isolated coreparticleswere incubatedat37 °Covernightwith anEPA
reaction buffer (50 mM Tris–HCl [pH 7.5], 75 mM NH4Cl, 1 mM EDTA,
25 mM MgCl2, 0.1% β-mercaptoethanol, 0.5% NP-40) supplemented
with 0.5 mMeach of dCTP, dGTP, dTTP, and 10 μCiα-32P-dATP (3000 Ci/
mmol). The 32P-labeled reaction mixtures were electrophoresed on 1%
agarose gel and subjected to autoradiography. The 32P-labeled DNAwas
extracted after the EPA reaction and separated via 1% agarose gel
electrophoresis.
Western blot analysis
Core particles were prepared as described above (Koschel et al.,
2000). In order to analyze the core (C, HBc) protein, the total lysates
were harvested and lysed in NP-40-containing lysis buffer (50 mM
Tris–HCl [pH 8.0], 150 mM NaCl, 1% NP-40). The lysates were then
cleared via centrifugation, and the supernatants were collected,
subjected to electrophoresis on SDS-polyacrylamide gel, and trans-
ferred to PVDF membranes. These membranes were incubated with
polyclonal rabbit anti-HBc (DAKO), monoclonal mouse anti-PPARγ
(Santa Cruz), polyclonal rabbit anti-adiponectin antibodies (Abcam),
or monoclonal mouse anti-tubulin (Calbiochem) antibodies. Immu-
noreactive bands were visualized with a horseradish peroxidase-
conjugated secondary antibody (DAKO) using enhanced chemical
luminescence (Amersham).
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